Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 171


Antiretroviral treatment strategies in highly treatment experienced perinatally HIV-infected youth.

Wong FL, Hsu AJ, Pham PA, Siberry GK, Hutton N, Agwu AL.

Pediatr Infect Dis J. 2012 Dec;31(12):1279-83. doi: 10.1097/INF.0b013e31826fd3e7.


Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.


Guidelines for using antiretroviral agents among HIV-infected adults and adolescents.

Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK; Panel on Clinical Practices for Treatment of HIV.

Ann Intern Med. 2002 Sep 3;137(5 Pt 2):381-433.


Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations of the Panel on Clinical Practices for Treatment of HIV.

Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK; Panel on Clinical Practices for the Treatment of HIV.

MMWR Recomm Rep. 2002 May 17;51(RR-7):1-55.


CD4+ and viral load outcomes of antiretroviral therapy switch strategies after virologic failure of combination antiretroviral therapy in perinatally HIV-infected youth in the United States.

Fairlie L, Karalius B, Patel K, van Dyke RB, Hazra R, Hernán MA, Siberry GK, Seage GR 3rd, Agwu A, Wiznia A; Pediatric HIV AIDS Cohort Study (PHACS), The International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT).

AIDS. 2015 Oct 23;29(16):2109-19. doi: 10.1097/QAD.0000000000000809.


Analyses of HIV-1 drug-resistance profiles among infected adolescents experiencing delayed antiretroviral treatment switch after initial nonsuppressive highly active antiretroviral therapy.

Agwu A, Lindsey JC, Ferguson K, Zhang H, Spector S, Rudy BJ, Ray SC, Douglas SD, Flynn PM, Persaud D; Pediatric AIDS Clinical Trials Group 381 Study Team.

AIDS Patient Care STDS. 2008 Jul;22(7):545-52. doi: 10.1089/apc.2007.0200.


Long-term Virologic Suppression Despite Presence of Resistance-associated Mutations Among Perinatally HIV-infected Youth.

Smith TT, Hsu AJ, Hutton N, Womble F, Agwu AL.

Pediatr Infect Dis J. 2015 Dec;34(12):1365-8. doi: 10.1097/INF.0000000000000895.


Potent and sustained antiviral response of raltegravir-based highly active antiretroviral therapy in HIV type 1-infected children and adolescents.

Briz V, León-Leal JA, Palladino C, Moreno-Perez D, de Ory SJ, De José MI, González-Tomé MI, Martín CG, Pocheville I, Ramos JT, Leal M, Muñoz-Fernández MÁ.

Pediatr Infect Dis J. 2012 Mar;31(3):273-7. doi: 10.1097/INF.0b013e31824580e8.


Cost-efficacy comparison among three antiretroviral regimens in HIV-1 infected, treatment-experienced patients.

Ruof J, Dusek A, DeSpirito M, Demasi RA.

Clin Drug Investig. 2007;27(7):469-79.


Virologic and immunologic response to highly active antiretroviral therapy in indigenous and nonindigenous HIV-1-infected patients in the Netherlands.

Nellen JF, Wit FW, De Wolf F, Jurriaans S, Lange JM, Prins JM.

J Acquir Immune Defic Syndr. 2004 Aug 1;36(4):943-50.


A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection.

Hecht FM, Wang L, Collier A, Little S, Markowitz M, Margolick J, Kilby JM, Daar E, Conway B, Holte S; AIEDRP Network.

J Infect Dis. 2006 Sep 15;194(6):725-33. Epub 2006 Aug 15.


Efficacy and tolerability of nevirapine- versus efavirenz-containing regimens in HIV-infected Thai children.

Lapphra K, Vanprapar N, Chearskul S, Phongsamart W, Chearskul P, Prasitsuebsai W, Chokephaibulkit K.

Int J Infect Dis. 2008 Nov;12(6):e33-8. doi: 10.1016/j.ijid.2007.10.008. Epub 2008 Jun 24.


Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: analysis of the HIV-2 Belgium and Luxembourg database.

Ruelle J, Roman F, Vandenbroucke AT, Lambert C, Fransen K, Echahidi F, Piérard D, Verhofstede C, Van Laethem K, Delforge ML, Vaira D, Schmit JC, Goubau P.

BMC Infect Dis. 2008 Feb 27;8:21. doi: 10.1186/1471-2334-8-21.


Response to zidovudine/didanosine-containing combination antiretroviral therapy among HIV-1 subtype C-infected adults in Botswana: two-year outcomes from a randomized clinical trial.

Bussmann H, Wester CW, Thomas A, Novitsky V, Okezie R, Muzenda T, Gaolathe T, Ndwapi N, Mawoko N, Widenfelt E, Moyo S, Musonda R, Mine M, Makhema J, Moffat H, Essex M, Degruttola V, Marlink RG.

J Acquir Immune Defic Syndr. 2009 May 1;51(1):37-46. doi: 10.1097/QAI.0b013e31819ff102.


Factors associated with mortality among persistently viraemic triple-antiretroviral-class-experienced patients receiving antiretroviral therapy in the HIV Outpatient Study (HOPS).

Palella FJ Jr, Armon C, Buchacz K, Chmiel JS, Novak RM, D'Aquila RT, Brooks JT; HOPS Investigators.

J Antimicrob Chemother. 2014 Oct;69(10):2826-34. doi: 10.1093/jac/dku190. Epub 2014 Jun 16.


Treatment limitations imposed by antiretroviral drug resistance mutations: implication for choices of first line regimens in resource-limited settings.

Mtambo A, Chan K, Shen A, Lima V, Hogg R, Montaner J, Moore D.

HIV Med. 2012 Mar;13(3):141-7. doi: 10.1111/j.1468-1293.2011.00950.x. Epub 2011 Nov 22.


Long-term outcomes in adolescents perinatally infected with HIV-1 and followed up since birth in the French perinatal cohort (EPF/ANRS CO10).

Dollfus C, Le Chenadec J, Faye A, Blanche S, Briand N, Rouzioux C, Warszawski J.

Clin Infect Dis. 2010 Jul 15;51(2):214-24. doi: 10.1086/653674.


Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.

Volmink J, Siegfried NL, van der Merwe L, Brocklehurst P.

Cochrane Database Syst Rev. 2007 Jan 24;(1):CD003510. Review. Update in: Cochrane Database Syst Rev. 2011;(7):CD003510.


[Structured therapeutic interruption in patients infected with HIV-1 experiencing a block in their antiretroviral treatment: preliminary results].

Rey D, Schmitt MP, Hess-Kempf G, Krantz V, Partisani M, Bernard-Henry C, Lang JM.

Pathol Biol (Paris). 2001 Sep;49(7):559-66. French.


A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study.

García F, Romeu J, Grau I, Sambeat MA, Dalmau D, Knobel H, Gomez-Sirvent JL, Arrizabalaga J, Cruceta A, Clotet BG, Podzamczer D, Pumarola T, Gallart T, O'Brien WA, Miró JM, Gatell JM.

AIDS. 1999 Dec 3;13(17):2377-88.


Supplemental Content

Support Center